Ill-fitting dentures as primary presentation of mantle cell lymphoma: A case report and literature review of the primary mantle cell lymphomas of the hard palate

Ömür Dereci, Sinan Ay, Mustafa Fuat Açıkalın¹, Mustafa Karagülle²
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Departments of ¹Pathology and ²Hematology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey

Address for correspondence:
Dr. Ömür Dereci,
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Eskişehir Osmangazi University, Meşelik Campus, 26480 Eskişehir, Turkey.
E-mail: omurdereci@hotmail.com

Received: 13-10-2014
Accepted: 27-07-2015

ABSTRACT
Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin’s lymphoma seen predominantly in males. Common extra-nodal sites of involvement of MCL are Waldeyer’s ring, gastrointestinal tract, bone marrow and peripheral blood. The extra-nodal palatal localization of MCL is quite uncommon. MCL is seen in predominantly older patients, therefore undiagnosed MCL patients are likely to have total prosthesis. In this study, a case of MCL, initially presenting as palatal swelling was reported with relevant literature review and the possible role of dental professionals in the diagnosis of this rare entity was discussed.

Key words: Hard palate, mantle cell lymphoma, non-Hodgkin lymphoma, oral lymphoma

CASE REPORT

A 71-year-old male patient was referred to Eskişehir Osmangazi University, Faculty of Dentistry, Department of Oral and Maxillofacial Surgery with a complaint of ill-fitting dentures. An intra-oral examination was performed and symmetric mucosal enlargements were observed on hard palate [Figure 1]. The mucosal swellings were asymptomatic. There were no pathologic findings on radiological examination. Patient was uncomfortable about the mobility of his dentures and had tried to fix them by sticking dish rags or other foreign materials into the prosthesis. Medical history was insignificant. Therefore, a provisional diagnosis of reactive mucosal lesion was made and incisional biopsy was performed under local anesthesia.

Microscopic examination revealed diffuse abundant small cells with hyperchromatic nuclei in the subepithelial region [Figure 2]. Mucosal ulceration was evident. Mild nuclear enlargement and pleomorphism were observed in...
Mantle cell lymphoma of the hard palate

Dereci, et al. 256

After the immunohistochemistry, tumoral cells showed strong positive staining with CD20 (L26, Ventana, Tucson) [Figure 4], pax-5 (SP34, Ventana, Tucson), CD5 (SP19, Ventana, Tucson), cyclin D1 (SP4-R, Ventana, Tucson) [Figure 5], bcl-2 (124, Ventana, Tucson) and IgM (poliklnal, Ventana, Tucson). Tumoral cells were partially stained with CD43 (L60, Ventana, Tucson). CD21 (SP104, Ventana, Tucson) and CD23 (SP23, Ventana, Tucson) immunostaining showed follicular dendritic cells. CD10 (SP67, Ventana, Tucson) and IgD (policional, Ventana, Tucson) were negative. Ki-67 proliferation index was 50%. The case was diagnosed as MCL with these findings. Patient was referred to Hematology Department of Eskisehir Osmangazi University, Faculty of Medicine for further evaluation and treatment.

Ultrasonography of abdomen revealed multiple lymphoadenopathies at mesenteric and para-aortic regions. After informed consent was taken, patient underwent cyclophosphamide, oncovin, prednol (COP) chemotherapy regimen. However, remission was not observed and the patient died after four chemotherapy cycles.

MATERIALS AND METHODS

English dental and medical literature search was conducted using the combination of terms such as hard palate, MCL, lymphoma and extra-nodal lymphoma in PubMed. Cases which were reported under the strict diagnosis of MCL and primarily located on the hard palate were extracted and data regarding treatment, follow-up and demographics was reviewed. Cases with secondary involvement were excluded from the study.

RESULTS

Nine publications with 14 cases defining primary hard palate MCLs published between 1990 and 2014 were identified. The mean age of earlier published cases was 67.1 years. Data
Mantle cell lymphoma of the hard palate

Dereci, et al.

regarding demographics and treatment of published cases are shown in Table 1.

DISCUSSION

MCL is a counterpart of non-Hodgkin lymphoma family and was first included in lymphoma classification in 2001. It originates from peripheral B-cells of mantle zone. MCL is relatively uncommon and occurs in middle aged adults with a male predilection.

Although MCL is mainly located in the lymph nodes, involvement of extra-nodal sites such as Waldeyer’s ring, peripheral blood, bone marrow and gastrointestinal tract are also reported.

Definite diagnosis of MCL is achieved with immunohistochemical staining with or without the assistance of molecular techniques. MCL tumoral cells commonly express CD20, CD5, CD43 antigens and BCL2 and cyclin D1 protein. However, they are CD10 and BCL6 negative and show negativity/weak positivity for CD23 antigen expression. Histologic examination reveals abundant monomorphous small-medium sized lymphoid cells with slightly/markedly irregular nuclear contours. The first impression on histologic appearance reminds of small cell lymphoma. Blastoïd and pleomorphic subtypes of MCL have been defined by WHO and it is suggested that blastoid or pleomorphic morphology are aggressive variants; similar histology may be seen in some cases at relapse.

Hard palate is an unusual site for primary MCL and this has been reported in the English literature several times. Kyo et al. reported that long term use of maxillary prosthesis might have provoked the lymphoid tissue accumulation and proliferation leading to a mass of MCL in the submucosal region of the hard palate. Guggisberg and Jordan reported that most oral MCLs occur in an elderly male population and have a predilection for the palate. The duration of the prosthesis usage of MCL patients could not be analyzed in the current literature review due to the unavailable data in the case reports. In the current case, patient was using total prosthesis for 10 years and the only complaint of the patient was the mobility of his dentures. The clinical appearance of the tumor suggested that the palatal accumulation of lymphoid mass might have been initiated by the long term use of the total prosthesis.

Other lymphoid tumors may primarily infiltrate hard palate similar to MCL. Milgrom and Yahalom reported nine cases of primary indolent lymphomas of the hard palate including MCL, follicular lymphoma and marginal zone lymphoma. There were two cases of MCL in their series and it is suggested that MCL cases showed more aggressive behavior compared to other lymphomas of the hard palate.

Polychemotherapy is mainly used to treat aggressive non-Hodgkin lymphomas including

| Authors               | Publication year | Number of cases | Age/sex | Treatment | Follow-up (months) |
|-----------------------|------------------|-----------------|---------|-----------|--------------------|
| Kyo et al. [7]        | 2010             | 1               | 71, male | CT        | NAD                |
| Chang et al. [8]      | 2003             | 1               | 62, female | CT     | 6                  |
| Aguilera et al. [13]  | 1998             | 1               | 55, male | NAD      | NAD                |
| Guggisberg and Jordan | 2010             | 2               | 67, male | Treatment declined | 1-24         |
|                       |                  |                 | 87, male | CT       | 2-8                |
| Scheller et al. [12]  | 2011             | 1               | 41, male | RT + CT, COD | 48              |
| Milgrom and Yahalom [11] | 2013         | 2               | 75, female | RT + CT, DOD | 41              |
| Kolokotronis et al. [17] | 2005     | 1               | 84, male | CT, DOD  | 17                |
| Fitzpatrick et al. [15] | 2012     | 4               | 57, male | CT, COD  | NDD               |
|                       |                  |                 | 67, female | RT, COD | NDD                |
|                       |                  |                 | 93, male  | NAD      | NAD                |
|                       |                  |                 | 63, female | CT, COD | NDD                |
| Costa et al. [16]     | 2014             | 1               | 61, male | CT, DOD  | NDD                |

RT: Radiotherapy, CT: Chemotherapy, NAD: Nonavailable data, COD: Clear of disease, DOD: Died of disease, NDD: Nondefinite data
MCL. (CHOP; cyclophosphamide, doxorubicin, vincristine, prednisolone[19]) Chang et al.[9] reported a polychemotherapy regimen consisting of Cytoxan, doxorubicin, vincristine and prednisone, in conjunction with rituximab administered every 3 weeks. Different chemotherapeutics achieve approximately high treatment response rate of 70%.[20-22] Meusers et al.[23] reported that the CHOP regimen did not show superiority to COP regimen in the treatment of MCL. Although CHOP-like antracycline containing chemotherapeutic combinations do not have distinct advantage on survival, they are currently chosen for standard therapeutic approach.[3] Radiation therapy is still a therapeutic option in low-stage disease (Ann Arbor stage 1, 2) In advance stage disease, the combination of radiotherapy and chemotherapy can be used, however, the efficacy of this combination have not been proven yet.

CONCLUSION

Primary MCL of the hard palate is a rare entity which is mostly seen in elder people. In this study, a case of palatal primary MCL which presents with ill-fitting total prosthesis is reported with clinical and histopathological features. Extensive literature review revealed 14 previously reported cases. Dental total prosthesis may mask the existing lesion on the hard palate, therefore, dental practitioner should be alert at the time of the clinical examination of patients with total or partial prosthesis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Harris NL, editor. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press: 2001.
2. Zhou Y, Wang H, Fang W, Romaguera JE, Zhang Y, Delassalle KB, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113:791-8.
3. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: Established therapeutic options and future directions. Ann Hematol 2004;83:71-7.
4. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Klun-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-65.
5. Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29-38.
6. Swerdlow SH, Campo E, Seto M, Müller-Hermelink HK. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. p. 229-32.
7. Kyö C, Kawaoka Y, Kinoshita K, Ohno H. Mantle cell lymphoma presenting with a tumor of the hard palate. Intern Med 2010;49:1663-6.
8. Chang CC, Rowe JJ, Hawkins P, Sadeghi EM. Mantle cell lymphoma of the hard palate: A case report and review of the differential diagnosis based on the histomorphology and immunophenotyping pattern. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:316-20.
9. Triantafillidou K, Dimitrakopoulos J, Iordanidis F, Gkagkalis A. Extranodal non-hodgkin lymphomas of the oral cavity and maxillofacial region: A clinical study of 58 cases and review of the literature. J Oral Maxillofac Surg 2012;70:2776-85.
10. Guggisberg K, Jordan RC. Mantle cell lymphoma of the oral cavity: Case series and comprehensive review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109:98-104.
11. Milgrom SA, Yahalom J. Indolent non-Hodgkin lymphoma primarily involving the hard palate: Outcome following radiotherapy. Leuk Lymphoma 2013;54:1208-11.
12. Scheller K, Becker S, Scheller C. Symmetric palatal swelling as the first clinical manifestation of a mantle cell non-Hodgkin’s lymphoma: A case report and review of literature. J Oral Maxillofac Pathol 2011;15:311-5.
13. Aguileras NS, Bijwaard KE, Duncan B, Krafth AE, Chu WS, Abbondanzo SL, et al. Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin’s lymphomas. Am J Pathol 1998;153:1969-76.
14. Tan KB, Tan LH, Soo R, Putti TC, Chong SM. Involvement of the appendix and palate by pleomorphic variant mantle cell lymphoma. Leuk Lymphoma 2006;47:1704-7.
15. Fitzpatrick SG, Al-Quran SZ, Fetner AE, Kuklan RM, Cohen DM, Bhattacharyya I. Mantle cell lymphoma of the hard palate: A series of 4 cases. Oral Surg 2012;5:76-83.
16. Costa FW, Chaves FN, Pereira KM, Alves AP, Sousa FB, Bêco MP, et al. Initial presentation of mantle cell lymphoma in the hard palate. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;117:e66.
17. Kolokotronis A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, et al. Localized B-cell non-Hodgkin’s lymphoma of oral cavity and maxillofacial region: A clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:303-10.
18. Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637-40.
19. van der Waal RI, Huijgens PC, van der Valk P, van der Waal I. Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the International Prognostic Index. Int J Oral Maxillofac Surg 2005;34:391-5.
20. Meusers P, Hense J, Brittinger G. Mantle cell lymphoma: Diagnostic criteria, clinical aspects and therapeutic problems. Leukemia 1997;11 Suppl 2:S60-4.
21. Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, Vaughan Hudson B, Pittaluga S, Anderson L, et al. The clinical
outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997;99:842-7.

22. Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257-62.

23. Meusers P, Engelhard M, Bartels H, Binder T, Füllle HH, Görg K, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 1989;7:365-80.